ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2020
The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- The LINC00920/miR-6834-3p/CPN1 Axis Modulates Immune Dysregulation in Sepsis-Associated Acute Kidney Injury and Serves as a Diagnostic Biomarker.Biochemical genetics · 2026Article
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Integrated Transcriptomic Analysis of S100A8/A9 as a Key Biomarker and Therapeutic Target in Sepsis Pathogenesis and AI Drug Repurposing.International journal of molecular sciences · 2025Article
- Identification of diagnostic candidate genes in COVID-19 patients with sepsis.Immunity, inflammation and disease · 2024Article
- Acute neutrophilic vasculitis (leukocytoclasia) in 36 COVID-19 autopsy brains.Diagnostic pathology · 2024Article
- Relationship between COVID-19 and ICU-Acquired Bloodstream Infections Related to Multidrug-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- Substantial heterogeneity of inflammatory cytokine production and its inhibition by a triple cocktail of toll-like receptor blockers in early sepsis.Frontiers in immunology · 2023Article
- Retinal microvascular morphology versus COVID-19: What to anticipate?Photodiagnosis and photodynamic therapy · 2022Article
- Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment.Journal of clinical medicine · 2022Article
- The evolving direct and indirect platforms for the detection of SARS-CoV-2.Journal of virological methods · 2022Review
- Regulation of acute reflectory hyperinflammation in viral and other diseases by means of stellate ganglion block. A conceptual view with a focus on Covid-19.Autonomic neuroscience : basic & clinical · 2022Review
- COVID-19 and SepsisTurkish journal of medical sciences · 2021Review
- Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.Chinese journal of natural medicines · 2021Article
- Article
- SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions.Biomedical journal · 2021Review
- Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers.Microorganisms · 2021Review
- Article
- Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19.Frontiers in pharmacology · 2020Article
- Do Ocular Fluids Represent a Transmission Route of SARS-CoV-2 Infection?Frontiers in medicine · 2020Review
- Magnitude of Septic Shock and its Associated Factors Among Critically Ill COVID-19 Patients at Addis Ababa COVID-19 Care Centers, Ethiopia.SAGE open nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.